Previous 10 | Next 10 |
Fulcrum Therapeutics, Inc. (FULC) Q4 2021 Earnings Conference Call March 3, 2022 8:00 A.M. ET Company Participants Christi Waarich - Director of Investor Relations Bryan Stuart - President and Chief Executive Officer Judy Dunn - President of R&D Esther Rajavelu - Chief Financial Officer C...
Fulcrum Therapeutics (NASDAQ:FULC) plans to begin a phase 3 trial, called REACH, of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD) in Q2 2022. FSHD is a rare genetic muscle disorder in which the muscles of the face, scapula, shoulders, upper arms and abdomen are ...
Fulcrum Therapeutics press release (NASDAQ:FULC): Q4 GAAP EPS of -$0.58 beats by $0.09. Revenue of $5.06M (+19.6% Y/Y) beats by $1.54M. CEO comment We announced today that we have a clear regulatory path forward for a Phase 3 trial that we believe is optimized to show losmapimod’s pote...
– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 – – On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022 – ...
Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for FSHD Fulcrum to host virtual Key Opinion Leader webcast on FSHD on March 24 at 10:00am...
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 202...
Fulcrum Therapeutics (NASDAQ:FULC) granted inducement awards outside of its 2019 Stock Incentive Plan to its newly appointed VP, Head of Market Value, Access and Policy Amy Winnen. The grant consisted of a non-statutory option to purchase up to 43,260 shares; option has an exer...
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fire...
First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initiation of Phase 1b trial in select hemoglobinopathies in 2Q 2022 On track to provide update on losmapimod in FSHD in 1Q 20...
CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of the Compan...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...